Clenaver 40

Orals

Clenaver 40

Clenaver 40 is a pharmaceutical-grade oral formulation of Clenbuterol Hydrochloride at 40 micrograms per tablet. Clenbuterol is a selective beta-2 adrenergic receptor agonist originally developed as a bronchodilator for the management of bronchospastic disorders. Its pronounced thermogenic and mild anabolic properties have made it one of the most widely researched compounds in metabolic pharmacology.

Mechanism of Action

Clenbuterol binds selectively to beta-2 adrenoceptors in bronchial smooth muscle and adipose tissue, producing smooth muscle relaxation and stimulating adenylate cyclase activity, which elevates intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A, initiating a downstream phosphorylation cascade that upregulates hormone-sensitive lipase — the rate-limiting enzyme in lipolysis. This mechanism drives enhanced fatty acid mobilization from adipocyte stores. Simultaneously, central and peripheral sympathomimetic effects increase basal metabolic rate and core temperature, further augmenting caloric expenditure.

Pharmacokinetic Profile

Following oral administration, clenbuterol is rapidly and extensively absorbed from the gastrointestinal tract with bioavailability of approximately 70–80%. The compound is widely distributed, with high affinity for lung and bronchial tissue as well as adipose depots. Plasma protein binding is approximately 50%. The elimination half-life is characteristically long at 36–48 hours, enabling once or twice-daily dosing regimens. Hepatic metabolism produces several inactive metabolites, with approximately 65% of the administered dose excreted renally as unchanged drug and glucuronide conjugates.

Beta-2 Receptor Down-Regulation

Extended continuous exposure to clenbuterol causes progressive down-regulation of beta-2 receptor density and reduced receptor sensitivity through internalization of receptor–ligand complexes. This pharmacological tolerance typically begins to manifest after 2–3 weeks of continuous administration. Structured cycling protocols — alternating administration periods with receptor recovery intervals — are used to maintain receptor sensitivity and preserve the thermogenic response across extended use periods.

Formulation

Each Clenaver 40 tablet contains 40 micrograms of Clenbuterol Hydrochloride as the active pharmaceutical ingredient, compounded with pharmaceutical-grade excipients including microcrystalline cellulose, lactose monohydrate, povidone, and magnesium stearate. Tablets are manufactured to BP specification under GMP-compliant conditions. Each production batch undergoes HPLC identity confirmation, concentration verification (specification: ±5% of label claim), dissolution testing, and microbiological limit testing prior to release.

Quality Assurance

Every batch of Clenaver 40 produced by Biomedica undergoes the complete pharmaceutical release testing protocol before distribution. This includes HPLC compound identity confirmation and purity analysis (specification: ≥98%), concentration verification (specification: ±5% of label claim), sterility testing per USP <71>, bacterial endotoxin quantification by LAL assay (specification: <0.25 EU/mL), and particulate matter inspection per USP <788>. A Certificate of Analysis is issued for every production lot.

Authentication

Each unit of Clenaver 40 carries a unique authentication code on its outer packaging. This code can be verified instantly on our Authentication page to confirm the product is genuine Biomedica stock.